Medical/Pharmaceuticals
BioDlink Accelerates Global Expansion with Bevacizumab Launch in Colombia and Pakistan
- BioDlink's bevacizumab injection secures marketing authorization in Colombia andPakistan following its recent approval in Nigeria, marking key regulatory milestones in high-need emerging markets. - GMP certification in Brazil, Colombia, and Argentina spans the top three most populous countries...
2025-08-13 20:00
2048
Daewoong Therapeutics Microneedle Patch Achieves Best-in-Class Bioavailability, Proving the Strength of Its Drug-Delivery Platform
* More than 80% relative bioavailability compared with injectable obesity therapy, well above the roughly 30% reported for existing microneedle patches and setting a new global benchmark * A potential game changer that addresses both the pain of injections and the low efficiency of oral form...
2025-08-13 15:36
1620
Ascletis Announces ASC47, a Muscle-Preserving Weight Loss Drug Candidate for Treatment of Obesity, Demonstrated Greater Efficacy with Tirzepatide than Semaglutide in a Preclinical Model
- The combination of ASC47 low dose with tirzepatide in diet-induced obese (DIO) mice resulted in an 87% greater reduction in body weight compared to tirzepatide monotherapy. - ASC47 low dose in combination with tirzepatide demonstrated statistically significantly greater incre...
2025-08-13 07:00
1868
VivaVision Strengthens Scientific Advisory Board with a World-Renowned Expert in Ophthalmology
WENZHOU, China, Aug. 12, 2025 /PRNewswire/ -- Recently, VivaVision Biotech ( Zhejiang) Co., Ltd. (VivaVision) announced the appointment of Quan Dong Nguyen, MD, MSc, FAAO, FARVO, FASRS to its Scientific Advisory Board. Quan Dong Nguyen, MD, MSc, FAAO, FARVO, FASRS, is currently a professor of oph...
2025-08-13 00:00
1905
Mabwell Announces First Patient Dosed in the US Clinical Study of Bulumtatug Fuvedotin in TNBC Patients Previously Treated with ADCs
SHANGHAI, Aug. 12, 2025 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced the first patient dosing in the U.S. for a clinical study of its novel nectin-4-targeting antibody-drug conjugate (Bulumtatug Fuvedotin, or BFv, R&D code: 9MW...
2025-08-12 22:00
1899
Aquedeon Medical Inc. Receives FDA Approval to Expand Clinical Trial of Duett Vascular Graft System
CAUTION: Investigational device. Limited by Federal (or United States) law to investigational use. SUNNYVALE, Calif., Aug. 12, 2025 /PRNewswire/ -- Aquedeon Medical Inc. (AMI) is pleased to announce that the U.S. Food and Drug Administration (FDA) has approved the expansion of its Investigationa...
2025-08-12 20:00
1514
Fosun Pharma's Small Molecule Innovative Drug XH-S004 Achieves Overseas Licensing for a Potential Total of $645 Million
SHANGHAI, Aug. 11, 2025 /PRNewswire/ -- On August 11, Fosun Pharma (SSE:600196, HKEX: 02196) announced that its subsidiary Fosun Pharma Industrial has signed a License Agreement withExpedition Therapeutics Inc.(Expedition) to grant Expedition the rights to develop, manufacture, and commercialize ...
2025-08-12 09:36
1712
AMI Pharm Advances AYP-101 to Phase 3, Paving the Way for a New Era in Fat-Reduction Injectable drugs
— Novel non-cytolytic injectable drug targets submental fat with significantly reduced pain and swelling — Phase 3 clinical trial underway in South Korea, following strong safety and efficacy results in earlier studies — AMI Pharm positions itself for global expansion in the multi-billion-dollar ...
2025-08-11 20:00
1768
Akeso Announces First Patient Dosed in Phase III Trial of Ivonescimab as Consolidation Therapy for Limited-Stage SCLC After Definitive Radiotherapy
HONG KONG, Aug. 10, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that the first patient has been dosed in its multicenter, randomized, double-blind Phase III study (AK112-311/HARMONi-9), evaluating ivonescimab, a first-in-class PD-1/VEGF bispecific antibody deve...
2025-08-11 10:52
1537
Hugel launches botulinum toxin Letybo in Malaysia
- The company strengthens brand experience for local medical professionals through academic events and hands-on workshops - It will solidify the market position of premium toxin products through Malaysian partner Venusys Medical SEOUL, South Korea, Aug. 10, 2025 /PRNewswire/ -- Hugel Inc., a lea...
2025-08-11 08:30
2000
Anbio Biotechnology Responds to Global Outbreaks with Chikungunya Rapid Test and New 15-Minute Ultra-Fast PCR System
Covering both mosquito-borne diseases and emerging respiratory pathogens, Anbio continues to advance point-of-care diagnostics for timely outbreak detection worldwide. FRANKFURT, Germany, Aug. 8, 2025 /PRNewswire/ -- In response to recent outbreaks of Chikungunya fever, Anbio Biotechnology has a...
2025-08-09 09:30
2921
WuXi XDC Included in MSCI China All Share Index
SHANGHAI, Aug. 8, 2025 /PRNewswire/ -- WuXi XDC Cayman Inc. ("WuXi XDC", stock code: 2268.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO) focused on the bioconjugate industry, today announced its inclusion in the MSCI China All Share Index, which unders...
2025-08-08 17:32
1775
Minghui Pharmaceutical Announces USD 131 Million Pre-IPO Financing to Advance Late-Stage Pipeline and Global Expansion
SHANGHAI, Aug. 7, 2025 /PRNewswire/ -- Minghui Pharmaceutical ("Minghui"), a late-stage clinical biopharmaceutical company, today announced the closing of a USD 131 million Pre-IPO financing led by new investors OrbiMed and co-led by Qiming Venture Partners. Further support came from existing inve...
2025-08-07 18:00
2638
US NCI Sponsors Senhwa Biosciences' Second Program-IND Submitted for Clinical Trial Targeting MYC-Aberrant Lymphoma
TAIPEI and SAN DIEGO, Aug. 7, 2025 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), a new drug development company focusing on first-in-class therapeutics for oncology, rare diseases, and infectious diseases, today announced that US National Cancer Institute (NCI) sponsors Senhwa's second ...
2025-08-07 14:35
1857
FDA approves expanded indication for AVTOZMA® (tocilizumab-anoh) intravenous (IV) formulation in cytokine release syndrome (CRS)
* Approval of AVTOZMA® (tocilizumab-anoh) intravenous infusion expands label to include treatment of adults and pediatric patients aged 2 years and older with cytokine release syndrome (CRS) [1] * AVTOMZA received FDA approval in January 2025, for multiple inflammatory indications including r...
2025-08-06 20:00
2123
The U.S. FDA Granted Fast Track Designation to Dizal's Birelentinib for Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
* Birelentinib (DZD8586) received Fast Track Designation from the U.S. FDA for relapsed/refractory CLL/SLL * Supporting data from a pooled analysis of phase I/II studies of birelentinib showed an objective response rate of 84.2% in heavily pretreated CLL/SLL patients SHANGHAI, Aug. 6, 2025 /P...
2025-08-06 19:02
1683
From AI to Precision Medicine: Taiwan's Smart Healthcare Innovations Shine at Taiwan Expo USA 2025
DALLAS, Aug. 5, 2025 /PRNewswire/ -- The Smart Healthcare Pavilion at Taiwan ExpoUSA 2025 will take place at the Kay Bailey Hutchison Convention Center in Dallas, Texas, from August 14 to 16. Featuring two world-leading hospitals and eight cutting-edge companies, the pavilion highlightsTaiwan's e...
2025-08-06 10:43
1699
WuXi AppTec Named Constituent of the FTSE4Good Index Series for Third Consecutive Year
SHANGHAI, Aug. 5, 2025 /PRNewswire/ -- WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services to enable companies in the pharmaceutical and life science industries, today announced its inclusion in the FTSE4Good Index Series for the third consecutive year....
2025-08-06 08:00
2249
Sanyou Bio Wins the "2025 Best Customer Satisfaction CRO Award"
SHANGHAI, Aug. 5, 2025 /PRNewswire/ -- The highly anticipated 7th China Bio Innovation Expo was recently held in grand fashion in Suzhou. At the awards ceremony onAugust 1, Sanyou Bio was honored with the "2025 Best Customer Satisfaction CRO Award" in recognition of its deep expertise and outstan...
2025-08-05 22:00
2600
FigureLabs: World's First AI scientific illustration tool for Effortless Publication Figures
OXFORD, United Kingdom, Aug. 5, 2025 /PRNewswire/ -- FigureLabs,
2025-08-05 21:00
1948
Week's Top Stories
Most Reposted
Never Miss a Message: Agoda's Customer Support Now Travels With You
[Picked up by 327 media titles]
2026-02-24 12:00
NextFin Asia: A New Dedicated Fund for the Catapult: Inclusion SE Asia Program to Further Scale Inclusive Finance Fintechs in ASEAN
[Picked up by 311 media titles]
2026-02-23 08:00
HBX Group and Traveloka expand strategic partnership to deepen APAC supply and accelerate global distribution
[Picked up by 307 media titles]
2026-02-26 09:30
Klook and Osaka Convention & Tourism Bureau sign MoU to advance inbound tourism and foster socio-economic development throughout Osaka Prefecture
[Picked up by 302 media titles]
2026-02-24 16:13
Amadeus acquires SkyLink to accelerate the deployment of AI in travel
[Picked up by 293 media titles]
2026-02-26 19:57
Most Read
/C O R R E C T I O N -- Republic Power Group Limited (NASDAQ: RPGL)/
2026-02-20 06:36
8845